A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence 'VANISH-2'

Trial Profile

A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence 'VANISH-2'

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs Polidocanol (Primary)
  • Indications Varicose veins
  • Focus Registrational; Therapeutic Use
  • Acronyms VANISH-2
  • Sponsors BTG; BTG International
  • Most Recent Events

    • 01 Apr 2014 The drug dosage has been changed as as reported by ClinicalTrials.gov record.
    • 04 Mar 2014 New trial record
    • 21 Feb 2014 One-year data from the VANISH-2 trial presented at the 26th Annual Meeting of the American Venous Forum, according to a BTG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top